Peripheral artery disease: How do genes and pharmacology interplay?
In patients with peripheral artery disease, high on-treatment platelet reactivity (HoTPR) might be associated with worse outcomes for those taking clopidogrel, but not for those taking aspirin. Certain genetic polymorphisms might account for HoTPR. Current literature supports the importance of antiplatelet therapy in treating patients with PAD with clopidogrel, aspirin, or both.